当前位置： SCI文献检索 > CHEST期刊下所有文献 > Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.

Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.

Abstract：

BACKGROUND:Vasodilatory shock refractory to catecholamine vasopressors and arginine vasopressin is highly morbid and responsible for significant mortality. Synthetic angiotensin II is a potent vasoconstrictor that may be suitable for use in these patients. RESEARCH QUESTION:What is the safety and effectiveness of angiotensin II and what variables are associated with a favorable hemodynamic response? STUDY DESIGN AND METHODS:We performed a multicenter, retrospective study at five tertiary medical centers in the United States. The primary end point of hemodynamic responsiveness to angiotensin II was defined as attainment of mean arterial pressure (MAP) of ≥ 65 mm Hg with a stable or reduced total vasopressor dosage 3 h after drug initiation. RESULTS:Of 270 included patients, 181 (67%) demonstrated hemodynamic responsiveness to angiotensin II. Responders showed a greater increase in MAP (+10.3 mm Hg vs +1.6 mm Hg, P < .001) and reduction in vasopressor dosage (-0.20 μg/kg/min vs +0.04 μg/kg/min; P < .001) compared with nonresponders at 3 h. Variables associated with favorable hemodynamic response included lower lactate concentration (OR 1.11; 95% CI, 1.05-1.17, P < .001) and receipt of vasopressin (OR, 6.05; 95% CI, 1.98-18.6; P = .002). In severity-adjusted multivariate analysis, hemodynamic responsiveness to angiotensin II was associated with reduced likelihood of 30-day mortality (hazard ratio, 0.50; 95% CI, 0.35-0.71; P < .001). Arrhythmias occurred in 28 patients (10%) and VTE was identified in 4 patients. INTERPRETATION:In postmarketing use for vasopressor-refractory shock, 67% of angiotensin II recipients demonstrated a favorable hemodynamic response. Patients with lower lactate concentrations and those receiving vasopressin were more likely to respond to angiotensin II. Patients who responded to angiotensin II experienced reduced mortality.

journal_name

Chest

journal_title

Chest

authors

Wieruszewski PM,Wittwer ED,Kashani KB,Brown DR,Butler SO,Clark AM,Cooper CJ,Davison DL,Gajic O,Gunnerson KJ,Tendler R,Mara KC,Barreto EF

doi

10.1016/j.chest.2020.08.2074

subject

Has Abstract

pub_date

2020-08-31 00:00:00

eissn

0012-3692

issn

1931-3543

pii

S0012-3692(20)34302-6

pub_type

杂志文章

在线工具

Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.